Fractyl Health, Inc. Common Stock
NASDAQ:GUTSBiotechnology
-$0.01 today
- Market cap
- $55.18M
- Beta
- 2.34
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$1.42
Volume 0.10M
Average 2.07M
GUTS Total Non-current Assets
All assets not expected to be converted to cash within one year.
Fractyl Health, Inc. Common StockNASDAQ: GUTS
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 7.0% from a year ago
Total non-current assets stood at $33.47M at the end of Q1 FY2026, down 7.0% from a year earlier and down 1.1% from the prior quarter. Over 3 fiscal years it compounded at +53.6% a year.
Context
- Total non-current assets amounted to 33.7% of total assets at the end of Q1 FY2026, down 9.7 pp from a year earlier.
- Total non-current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -7.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 33.83M USD
- Year-over-year change
- -6.9%
- 4-year CAGR
- +53.1%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.83M | -6.9% |
| FY2024 | 2024-12-31 | 36.31M | -10.5% |
| FY2023 | 2023-12-31 | 40.56M | +334.9% |
| FY2022 | 2022-12-31 | 9.33M | +51.4% |
| FY2021 | 2021-12-31 | 6.16M | — |
Total Non-current Assets vs competitors
How GUTS compares with its peers on the latest reported figures
- GUTS's Mar 2026 total non-current assets of $33.47M is the 2nd highest of the 7 companies compared; the peer median is $19.12M.
- Its year-over-year change of -7.0% is the 2nd highest of 7, against a peer median of -17.9%.
- Total non-current assets amounts to 33.7% of total assets for GUTS, versus a peer median of 15.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $35.2M | -16.8% | -3.0% | 24.5% | |
| Mar 2026 | $33.47M | -7.0% | +53.6% | 33.7% | |
| Mar 2026 | $32.76M | +78.4% | -38.4% | 18.4% | |
| Mar 2026 | $21.02M | -38.2% | -24.8% | 8.7% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $17.22M | -19.0% | -13.6% | 16.2% |
| Mar 2026 | $12.08M | -13.6% | -2.3% | 15.2% | |
| Mar 2026 | $67K | -99.4% | -64.3% | 0.1% | |
| Peer median (excluding GUTS) | $19.12M | -17.9% | -19.2% | 15.7% | |
Competitors are the stored peer set for GUTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 95.47M | 49.27M | 33.52M | 67.46M | 81.54M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 22K | 0 | 0 |
| Inventory | 0 | 0 | 73K | 73K | 0 |
| Other Current Assets | 915K | 2.36M | 2.03M | 4.23M | 6.04M |
| Total Current Assets | 96.39M | 51.63M | 35.65M | 71.76M | 87.58M |
| Property, Plant & Equipment (Net) | 1.35M | 1.65M | 30.77M | 31.39M | 29.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 863K | 835K | 0 | 0 |
| Long-term Investments | 0 | 4.26M | 4.26M | 4.26M | 4.26M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 4.82M | 2.56M | 4.7M | 666K | 337K |
| Total Non-current Assets | 6.16M | 9.33M | 40.56M | 36.31M | 33.83M |
| Total Assets | 102.55M | 60.96M | 76.21M | 108.08M | 121.4M |
| Account Payables | 970K | 980K | 553K | 3.24M | 1.57M |
| Short-term Debt | 15.72M | 0 | 2.73M | 0 | 5.1M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | (970K) | (980K) | 0 | 0 | 0 |
| Other Current Liabilities | 5.13M | 3.3M | 4.4M | 7.4M | 6M |
| Total Current Liabilities | 23.65M | 7.31M | 11.19M | 19.78M | 18.33M |
| Long-term Debt | 287.33M | 305.09M | 342.48M | 30.16M | 30.59M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 555K | 409K | 19.1M | 2.33M | 37.07M |
| Total Non-current Liabilities | 288.22M | 305.96M | 390.09M | 59.88M | 93.62M |
| Total Liabilities | 311.87M | 313.28M | 401.27M | 79.65M | 111.94M |
| Common Stock | 0 | 0 | 0 | 0 | 1K |
| Retained Earnings | (223.07M) | (269.53M) | (346.62M) | (415.31M) | (556.26M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (209.33M) | (252.32M) | (325.06M) | 28.42M | 9.46M |
| Total Debt | 304.34M | 306.81M | 373.72M | 62.5M | 61.65M |
| Net Debt | 208.87M | 257.54M | 340.2M | (4.96M) | (19.89M) |
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
Intrinsic Alpha fair value
Locked
Current Price
$4.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.